ArticleFrontiers in pharmacology2023

Elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis ineligible for clinical trials: a 24-week observational study.

Libor Fila et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.